These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30585395)

  • 1. Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Alvino A; Magatti M; Silini AR; Cardinale A; Paldino E; Fusco FR; Parolini O
    J Cell Mol Med; 2019 Feb; 23(2):1581-1592. PubMed ID: 30585395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
    Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
    PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
    Giampà C; Montagna E; Dato C; Melone MA; Bernardi G; Fusco FR
    PLoS One; 2013; 8(5):e64037. PubMed ID: 23700454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease.
    Paldino E; Balducci C; La Vitola P; Artioli L; D'Angelo V; Giampà C; Artuso V; Forloni G; Fusco FR
    Mol Neurobiol; 2020 Apr; 57(4):1889-1903. PubMed ID: 31879858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B Lymphocytes as Targets of the Immunomodulatory Properties of Human Amniotic Mesenchymal Stromal Cells.
    Magatti M; Masserdotti A; Bonassi Signoroni P; Vertua E; Stefani FR; Silini AR; Parolini O
    Front Immunol; 2020; 11():1156. PubMed ID: 32582218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.
    Canals JM; Pineda JR; Torres-Peraza JF; Bosch M; Martín-Ibañez R; Muñoz MT; Mengod G; Ernfors P; Alberch J
    J Neurosci; 2004 Sep; 24(35):7727-39. PubMed ID: 15342740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice.
    Pang TYC; Stam NC; Nithianantharajah J; Howard ML; Hannan AJ
    Neuroscience; 2006 Aug; 141(2):569-584. PubMed ID: 16716524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis.
    Fink KD; Rossignol J; Crane AT; Davis KK; Bombard MC; Bavar AM; Clerc S; Lowrance SA; Song C; Lescaudron L; Dunbar GL
    Stem Cell Res Ther; 2013 Oct; 4(5):130. PubMed ID: 24456799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
    Strand AD; Baquet ZC; Aragaki AK; Holmans P; Yang L; Cleren C; Beal MF; Jones L; Kooperberg C; Olson JM; Jones KR
    J Neurosci; 2007 Oct; 27(43):11758-68. PubMed ID: 17959817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Downregulation of p75
    Suelves N; Miguez A; López-Benito S; Barriga GG; Giralt A; Alvarez-Periel E; Arévalo JC; Alberch J; Ginés S; Brito V
    Mol Neurobiol; 2019 Feb; 56(2):935-953. PubMed ID: 29804232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
    Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
    Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
    J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor skill learning modulates striatal extracellular vesicles' content in a mouse model of Huntington's disease.
    Solana-Balaguer J; Garcia-Segura P; Campoy-Campos G; Chicote-González A; Fernández-Irigoyen J; Santamaría E; Pérez-Navarro E; Masana M; Alberch J; Malagelada C
    Cell Commun Signal; 2024 Jun; 22(1):321. PubMed ID: 38863004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.
    Cardinale A; Paldino E; Giampà C; Bernardi G; Fusco FR
    PLoS One; 2015; 10(8):e0134482. PubMed ID: 26252217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TYROBP/DAP12 knockout in Huntington's disease Q175 mice cell-autonomously decreases microglial expression of disease-associated genes and non-cell-autonomously mitigates astrogliosis and motor deterioration.
    Creus-Muncunill J; Haure-Mirande JV; Mattei D; Bons J; Ramirez AV; Hamilton BW; Corwin C; Chowdhury S; Schilling B; Ellerby LM; Ehrlich ME
    J Neuroinflammation; 2024 Mar; 21(1):66. PubMed ID: 38459557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenously Infusing the Secretome of Adipose-Derived Mesenchymal Stem Cells Ameliorates Neuroinflammation and Neurological Functioning After Traumatic Brain Injury.
    Xu C; Diao YF; Wang J; Liang J; Xu HH; Zhao ML; Zheng B; Luan Z; Wang JJ; Yang XP; Wei MG; Duan JH; Wang KQ; Chen C; Chen F; Ming D; Zhang S; Sun HT; Li XH
    Stem Cells Dev; 2020 Feb; 29(4):222-234. PubMed ID: 31830866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
    Anglada-Huguet M; Giralt A; Rué L; Alberch J; Xifró X
    Biochim Biophys Acta; 2016 Jul; 1862(7):1255-66. PubMed ID: 27063456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.